Back

New Royal Decree Analyzed in 'Conference on Clinical Trials.'

20-09-2017
New Royal Decree Analyzed in 'Conference on Clinical Trials.'New Royal Decree Analyzed in 'Conference on Clinical Trials.'New Royal Decree Analyzed in 'Conference on Clinical Trials.'New Royal Decree Analyzed in 'Conference on Clinical Trials.'New Royal Decree Analyzed in 'Conference on Clinical Trials.'New Royal Decree Analyzed in 'Conference on Clinical Trials.'
New Royal Decree Analyzed in 'Conference on Clinical Trials.'New Royal Decree Analyzed in 'Conference on Clinical Trials.'New Royal Decree Analyzed in 'Conference on Clinical Trials.'New Royal Decree Analyzed in 'Conference on Clinical Trials.'New Royal Decree Analyzed in 'Conference on Clinical Trials.'New Royal Decree Analyzed in 'Conference on Clinical Trials.'
The collaboration between the European University and BioClever is still paying off, on this occasion, by holding the ‘Conference on Clinical Trials’ with the participation of many highly regarded speakers.

The first participant was Dr. Ángel Navarro, president and founder partner of Azierta, who presented the main changes in the New Royal Decree (RD) 1090/2015. Furthermore, he outlined a national picture of clinical research, times and efforts, both financial and human, that are necessary to put a new medication within society's reach.

Next,  Dr. Antonio Portolés, director of the Foundation for Biomedical Research of the Hospital Clínico San Carlos, focused his presentation on non-commercial research promoted from public hospitals or scientific associations. In order to develop this type of studies, he mentioned the vital importance of  obtaining grants from governments and supranational authorities.

The last presentation was given by Ana Isabel Terleira, Vice-president of the Ethical Committee of the Hospital de Alcorcón and clinical pharmacologist at the Hospital Clínico San Carlos, who focused on determining the implications of the New Royal Decree for CRECs (Clinical Research Ethics Committees) and how this affects the process in hospitals and several sponsors.

The conference ended with a discussion forum between speakers and attendees, moderated by Eva Martín, founding partner of Kinrel, in which the main concerns were related with the difficulty to unify processes. The importance of clinical research for the advance of medicine and improving patients' quality of life was also discussed. Among the attendees, there were several investigators, research personnel from scientific associations, persons responsible for scientific research foundations of public and private hospitals of the community of Madrid, and many representatives from medical and clinical surgery departments from several renown pharmaceutical and biotechnological laboratories.
Share

Related news

eCRFs: a new online data collection system
20-09-2017

eCRFs: a new online data collection system

To conduct a clinical trial, electronic data collection is currently becoming more common, because new technologies enable us to gather information in a faster and more streamlined way, with the quality assurance required by the end purpose of collecting such data.
Regulations concerning clinical trials with drug products
20-11-2016

Regulations concerning clinical trials with drug products

At the 11th Congress held by the Medical Association of the Pharmaceutical Industry (AMIFE, as per the Spanish acronym), held on November 12-14 in Madrid, one of the issues discussed was the status of the Clinical Trial Royal Decree, which is currently awaiting the ruling of the State Council, since the text is almost finished, as stated by Mr. César Hernández, Head of the Committee on Medicinal Products for Human Use of the Spanish Agency of Medicinal Products and Medical Devices (AEMPS).